{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "gogce crynen"}, {"accession": "MS:1000589", "name": "contact email", "value": "gcrynen@scripps.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "The scripps research institute"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Srinivasa Subramaniam"}, {"accession": "MS:1000589", "name": "contact email", "value": "SSubrama@scripps.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Associate Professor, Neuroscience, The Scripps Research Institute Florida"}]}], "datasetFiles": [{"accession": "MS:1002845", "name": "Associated file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/uniprot_mouse_filtered_proteome_UP000000589.fasta"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX1_NonPHOSPHO.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX1_PHOSPHO.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX2_NonPHOSPHO.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX2_PHOSPHO.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX3_NonPHOSPHO.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX3_PHOSPHO.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX1_NonPHOSPHO.msf"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX1_PHOSPHO.msf"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX2_NonPHOSPHO.msf"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX2_PHOSPHO.msf"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX3_NonPHOSPHO.msf"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX3_PHOSPHO.msf"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX1_3_PHOSPHO.mzTab"}, {"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434/MS219033_NS_SS_PLEX1_3_NonPHOSPHO.mzTab"}], "description": "The therapeutic benefits of L\u20133,4\u2013dihydroxyphenylalanine (L-DOPA) in Parkinson\u2019s disease (PD) patients severely diminishes with the onset of L-DOPA-induced dyskinesia (LID), a debilitating motor side effect. LID is mainly due to altered dopaminergic signaling in the striatum, a brain region that controls motor and cognitive functions. However, the molecular mechanisms that promote LID remain unclear. Here, we have reported that increased striatal RasGRP1 (also known as CalDAG-GEF-II) is instrumentally linked to the development of LID in a 6-hydroxydopamine (6-OHDA) lesioned mouse model of PD. L-DOPA treatment rapidly upregulated RasGRP1 in the dopamine-1 receptor positive neurons in the dorsal striatum. RasGRP1 deleted mice (RasGRP1\u2013/\u2013) had drastically diminished LID, and RasGRP1\u2013/\u2013 mice did not interfere with the therapeutic benefits of L-DOPA. In terms of its mechanism, RasGRP1 mediated L-DOPA-induced extracellular regulated kinase (ERK), the mammalian target of rapamycin kinase (mTOR) and the cAMP/PKA pathway. RasGRP1 bind directly with and acts 2 as a guanine nucleotide exchange (GEF) for Ras-homolog-enriched in the brain (Rheb), a potent activator of mTOR, both in vitro and in the intact striatum. High-resolution tandem mass tag mass spectrometry analysis of striatal tissue revealed significant targets, such as phosphodiesterase 10a (Pde10a), Pde2a, catechol-o-methyltransferase (Comt), and glutamate decarboxylase 1 and 2 (Gad1 and Gad2), as downstream regulators of RasGRP1 that are linked to LID vulnerability. Moreover, we found that RASGRP1 protein is also upregulated predominantly in the striatum of MPTP-lesioned macaque treated with L-DOPA, emphasizing the translational potential of this protein. Collectively, the findings of this study demonstrated that RasGRP1 is a major regulator of LID in the dorsal striatum. Pharmacological or gene-depletion strategies targeting RasGRP1 may offer novel therapeutic opportunities for preventing LID in PD patients.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/05/PXD017434"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD017434"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD017434"}], "instruments": [{"accession": "MS:1002416", "name": "Orbitrap Fusion"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "RasGRP1, dyskinesia, Parkinson Disease"}, {"accession": "MS:1001926", "name": "curator keyword", "value": "Biomedical"}], "modifications": [{"accession": "MOD:00696", "name": "phosphorylated residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "32426479"}, {"accession": "MS:1002866", "name": "Reference", "value": "Eshraghi M, Ram\u00edrez-Jarqu\u00edn UN, Shahani N, Nuzzo T, De Rosa A, Swarnkar S, Galli N, Rivera O, Tsaprailis G, Scharager-Tapia C, Crynen G, Li Q, Thiolat ML, Bezard E, Usiello A, Subramaniam S. RasGRP1 is a causal factor in the development of l-DOPA-induced dyskinesia in Parkinson's disease. Sci Adv. 2020 6(18):eaaz7001"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Mus musculus (Mouse)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "10090"}]}], "title": "RasGRP1 is a Causal Factor in the Development of L-DOPA-induced dyskinesia in Parkinson Disease"}